Mangoceuticals (NASDAQ:MGRX – Get Free Report) and Encompass Health (NYSE:EHC – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.
Analyst Recommendations
This is a summary of recent ratings and target prices for Mangoceuticals and Encompass Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Encompass Health | 0 | 1 | 5 | 1 | 3.00 |
Encompass Health has a consensus target price of $148.20, suggesting a potential upside of 21.69%. Given Encompass Health’s stronger consensus rating and higher probable upside, analysts clearly believe Encompass Health is more favorable than Mangoceuticals.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mangoceuticals | $460,000.00 | 19.69 | -$20.64 million | ($1.01) | -0.42 |
| Encompass Health | $5.94 billion | 2.02 | $566.20 million | $6.14 | 19.84 |
Encompass Health has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Encompass Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Mangoceuticals and Encompass Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
| Encompass Health | 10.01% | 18.08% | 8.22% |
Insider & Institutional Ownership
56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 97.3% of Encompass Health shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 1.8% of Encompass Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Mangoceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Encompass Health has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Summary
Encompass Health beats Mangoceuticals on 12 of the 15 factors compared between the two stocks.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions. It offers services through the Medicare program to federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. The company was incorporated in 1984 and is based in Birmingham, Alabama.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
